Abstract
ONe hundred patients with Paget's disease of bone were treated with salmon calcitonin. Seventy per cent of patients who presented with pain reported improvement of symptoms. Side effects which occurred in 53 patients were more severe in women, necessitating the withdrawal of therapy in 30% of women as against 7.5% of men. Five of the patients with intolerable side effects were subsequently able to tolerate porcine calcitonin, while six were unable to tolerate salmon, porcine or human calcitonin. No audiological improvement occurred. Aortic valve lesions were detected in 11 patients. After a mean treatment period of 7.8 months, serum alkaline phosphatase level was reduced by 39.3%. Total 24-hour urinary hydroxyproline was reduced by 46.1% after 11.2 months of treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
